Abstract. Previous studies have shown that cannabinoid 2 (CB 2 )-receptor agonists might have analgesic effects on visceral hypersensitivity. To extend these results, we have determined the pharmacological characteristics of a newly designed
Introduction
Activation of cannabinoid receptors is known to induce various pharmacological effects in the gastrointestinal tract (1, 2) . Two cannabinoid receptor subtypes, cannabinoid 1 (CB 1 ) and cannabinoid 2 (CB 2 ) receptors, both of which are G protein-coupled receptors, have been identified and cloned. CB 1 receptors are mostly expressed in the central and peripheral nervous systems (3, 4) , while CB 2 receptors are mostly expressed in immune cells, such as mast cells, and the peripheral nervous system (5, 6) . Activation of CB 1 receptors in the central nervous system produces a number of psychoactive effects, including hypothermia, catalepsy, and hypolocomotion in rats; hence, the therapeutic use of systemically administered nonselective cannabinoid (CB) agonists or CB 1 receptor-selective agonists may be limited. In contrast, activation of CB 2 receptors has no psychoactive effects in rats (7, 8) and therefore is of particular therapeutic interest. A recent study using CB 2 -receptors knock-out mice showed that the CB 2 agonist AM1241 modulates visceral afferent responses to the immunogenic agent bradykinin via activation of CB 2 receptors (9). In the colitis-induced hypersensitivity model, the CB 2 agonist JWH015 reduced the abdominal responses to rectal distension mediated by CB 2 receptors (10). These results suggest that CB 2 agonists might have analgesic effects on visceral hypersensitivity. To explore the possible use of CB 2 agonists to treat functional gut disorders associated with visceral hypersensitivity, such as irritable bowel syndrome (IBS), we have synthesized a novel CB 2 
, which is a derivative of benzimidazolone ( Fig. 1) . Here, we have determined the affinity of PF-03550096 for the CB 1 and CB 2 receptors and examined whether it shares the ability of cannabinoid receptor agonists to inhibit forskolin-stimulated cyclic adenosine monophosphate (cAMP) production in Chinese hamster ovary (CHO) cells expressing CB 1 or CB 2 receptors. Furthermore, we examined the effects of PF-03550096 on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced visceral hypersensitivity in vivo.
Materials and Methods

Materials
PF-03550096 and N-(1S)-endo-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl-5-(4-chloro-3-methylphenyl)-1(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528) were synthesized at Pfizer Global Research Development (PGRD) Nagoya Laboratories (Aichi). was dissolved in DMSO/ PEG400 (1:19). The solvent alone had no effect on the responses in the in vivo studies.
Membrane preparation and binding HEK293 cells expressing human CB 1 (hCB 1 ) receptors and CHO-K1 cells expressing human CB 2 (hCB 2 ) receptors were obtained from PGRD Groton laboratories (Groton, CT, USA). CHO-K1 cells stably expressing rat CB 2 (rCB 2 ) receptors were obtained from PGRD Nagoya Laboratories. Cells transfected with hCB 1 , hCB 2 , or rCB 2 were grown in flasks containing F-12 medium supplemented with 10% FBS, 20 mM HEPES, 100 units / ml penicillin, 100 µl / ml streptomycin, and 500 µg / ml geneticin. Harvested cells were homogenized in ice-cold 50 mM Tris-HCl containing protease inhibitor cocktail, followed by centrifugation at 1000 × g for 10 min at 4°C. The supernatant was centrifuged at 40,000 × g for 10 min at 4°C, and the pellets were suspended in 50 mM Tris-HCl (pH 7.4). The suspension was centrifuged once more in the same manner, and the pellet was resuspended in 50 mM Tris-HCl (pH 7.4). For the rat CB 1 (rCB 1 ) binding assay, whole brains were collected from euthanized male Sprague-Dawley rats purchased from Charles River, Inc. Competitors were present at varying concentrations, and the nonspecific binding of the radioligands was determined in the presence of 10 µM CP55,940 for CB 2 binding assays or 10 µM AM251 for CB 1 binding assays. Reactions were incubated for 60 min at 25°C, and then 100 µl stop buffer (TME buffer containing 5% BSA) was added. The assays were terminated by filtration using a Unifilter cell harvester (Perkin Elmer) followed by three washes of 25 mM Tris-HCl (pH 7.4 at 25°C) onto Unifilter 96 well GF / B filtermats. After harvesting, the filtermats were dried for 60 min at 50°C. Radioactivity was measured by scintillation counting using the Packard Top-Count Microplate Scintillation Counter. Binding isotherms were analyzed by non-linear regression using GraphPad Prism ver.2.01 (San Diego, CA, USA). 
Cell-based cAMP functional assay
Cellular cAMP was measured using HTRF cAMP dynamic reagent purchased from CISBIO (Cedex, France). CHO-K1 cells expressing hCB 1 or hCB 2 receptors were obtained from PGRD Groton laboratories and were grown in flasks containing F-12 medium supplemented with 10% FBS, 20 mM HEPES, 50 units/ ml penicillin, 50 µl / ml streptomycin, and 500 µg / ml geneticin. For the hCB 1 functional assay, cells expressing hCB 1 were harvested, resuspended in incubation buffer (F-12 medium, 20 mM HEPES, 1 mM IBMX, and 1 mg / ml acid-free BSA), and dispensed into 384-well plates at a density of 1.0 × 10 3 cells / well in the presence or absence of test compounds. Cells were incubated with 10 µM forskolin at 37°C for 30 min, and the cAMP-XL665-conjugated antibody and the anti-cAMP-cryptase-conjugated antibody were added to the plate. After incubation for 60 min at room temperature, measurements were made using a Wallac 1420 ARVOsx multilabel counter (Perkin Elmer). Data analysis was performed based on the ratio of fluorescence intensity of each well at 620 and 665 nm. The sigmoidal dose-response equation was used to determine EC 50 and E max values. These values represent the relative efficacy that was defined as the ratio of the response of test compound to the maximum response of 2-arachidonoylglycerol. For the hCB 2 functional assay, cells expressing hCB 2 were harvested, re-suspended in incubation buffer (F-12 medium, 20 mM HEPES, 1 mM IBMX, and 0.1 mM Ro-20-1724), and dispensed into 96-well plates at a density of 2.5 × 10 3 cells / well in the presence or absence of test compounds. Reactions were initiated by adding 5 µM forskolin at 37°C, and the assay was carried out as described above.
Animals
Male Sprague-Dawley rats (240 -270 g) were purchased from Charles River, Inc. and were housed in pairs in polypropylene cages with free access to food and water. The animals were kept under conditions of constant temperature (23 ± 2°C) and humidity (55 ± 15%) with a 12-h light / dark cycle (lights on 7:00 a.m.). All experiments employed in this study were approved by the Animal Ethics Committee of Nagoya Laboratories, PGRD, according to the Laboratory Animal Welfare guidelines.
Visceral hypersensitivity model
Rats were fasted for 16 -18 h before surgery and were anesthetized by intramuscular injection of ketamine (20 mg / kg) and xylazine (3 mg / kg). After abdominal laparotomy, TNBS was injected into the proximal colon (1 cm from the cecum) at a dosage of 50 mg / kg in 0.5 ml 30% ethanol. Sham animals underwent the same surgery but were not administered TNBS. Seven days after surgery, colonic pain threshold was measured as previously reported (11, 12) . Animals were fasted for 16 -18 h and then placed individually into polypropylene cages. After acclimation, a latex balloon (5-cm in length; Okamoto, Tokyo) was placed in the distal colon 5 cm from the anus, and it was fixed at the tail with tape. The balloon was progressively inflated from 0 to 70 mmHg, by 5-mmHg increments every 30 s, using an electronic barostat purchased from G&J Electronics, Inc. (Willowdale, Ontario, Canada). The colonic pain threshold was determined as the pressure required to elicit behavioral signs of pain (13, 14) .
Pharmacokinetic study
The blood samples were drawn from the jugular vein at specified time intervals after oral or subcutaneous administration of PF-03550096 or SR144528, respectively. The blood samples (100 µl) were precipitated by adding 1 ml acetonitrile and then centrifuged at 10,000 × g for 10 min. The supernatant was analyzed for drug concentration by using a mass spectrometer (API-300; MDS Sciex, Ontario, Canada) equipped with an HPLC system (HP1100; Agilent Technologies, Palo Alto, CA, USA).
Data analyses
The data obtained from colonic distension studies are represented as the median and first and third quartiles that indicate the range of median values calculated by GraphPad Prism Software ver. 2.01. The data were subjected to the individual Mann-Whitney U-test. Statistical significance was determined at P<0.05.
Results
Ligand binding assays
To 3 H]CP55,940 bound to human and rat CB 2 receptors with high affinities (hCB 2 : 7.9 ± 1.7 nM, rCB 2 : 47 ± 5.6 nM), whereas it showed lower affinities to human and rat CB 1 receptors (hCB 1 : 1500 ± 180 nM, rCB 1 : 1300 ± 210 nM). The selectivity ratios of PF-03550096 for the human and rat CB 2 receptors were higher than those of CP55,940.
cAMP assays
The ability of PF-03550096 to activate CB receptors was assessed in a functional cAMP accumulation assay using cells expressing human CB 1 or CB 2 receptors (Table 2) . Similar to WIN55,212-2, PF-03550096 potently inhibited forskolin-mediated cAMP production by human CB 2 receptors, with an EC 50 value of 2.1 ± 0.50 nM. In contrast, the EC 50 value of PF-03550096 on human CB 1 receptors was 450 ± 250 nM; this indicates a 213-fold selectivity ratio for human CB 2 receptors. In addition, both PF-03550096 and WIN-55,212-2 showed maximum inhibition of forskolinmediated cAMP production by human CB 2 receptors, with Emax values of 120 ± 5.7% and 110 ± 4.7%, respectively.
PF-03550096 inhibited TNBS-induced decreased colonic pain threshold in rats
Seven days after surgery, the colonic pain threshold in response to colonic distension was measured in sham and TNBS-treated rats. We observed a decreased pain threshold in animals treated with TNBS in comparison to sham animals (Fig. 2) . Oral administration of PF-03550096 (3, 10 mg / kg) inhibited the TNBS-induced decrease in pain threshold with statistical significance. No abnormal behaviors were observed during the experimental period.
SR144528 reversed the inhibitory effects of PF-03550096 in TNBS-treated rats
We examined whether the inhibitory effects of PF-03550096 could be reversed by the CB 2 -selective antagonist SR144528. Inhibitory effects of PF-03550096 (10 mg / kg) were reproducibly observed with statistical significance; these effects were reversed by subcutaneous pretreatment with SR144528 (10 mg / kg). SR144528 itself did not modulate the pain threshold (Fig. 3) .
Plasma concentrations of PF-03550096 and SR144528
Pharmacokinetics studies of PF-03550096 (1 mg / kg) and SR144528 (10 mg / kg) were assessed in the rat. After the oral administration of PF-03550096, the plasma concentration reached its maximum (21 ± 4.9 ng / ml) at 30 min after dosing and gradually decreased up to 8 h. The plasma concentration of SR144528 gradually increased post dosing and saturated at 4 h after subcutaneous administration (33 ± 11 ng / ml). Data represent the mean ± S.E.M. from at least three separate experiments each performed in dupulicate. Each value represents the mean ± S.E.M. of three series of experiments, each of which was run by duplicate measurement. 
Discussion
The purpose of this study was to elucidate the in vitro characteristics of PF-03550096, a newly synthesized CB 2 ligand, and to determine the effects of PF-03550096 in the TNBS-induced visceral hypersensitivity model. Binding data showed that the selectivity of PF-03550096 for hCB 2 and rCB 2 receptors were higher than those of CP55,940. Notably, PF-03550096 had 190-fold selectivity for hCB 2 over hCB 1 . Both CB 1 and CB 2 coupled to Gi reduce cAMP upon receptor stimulation (15) . Generally, a ligand that reduces cAMP via receptor binding is defined as an agonist. We therefore tested PF-03550096 in a cAMP accumulation assay to determine whether this compound is an agonist or an antagonist. In this assay, PF-03550096 behaved as a full agonist upon binding human CB 2 receptors and displayed 210-fold selectivity for hCB 2 over hCB 1 receptors. An advantage of this CB 2 selectivity ratio is a reduced possibility of affecting the central nervous system and causing clinically adverse effects mediated by CB 1 receptors. To evaluate the utility of PF-03550096 for studying the role of CB 2 receptors in vivo, we characterized its pharmacokinetic properties in rats. PF-03550096 was rapidly absorbed following oral administration with peak plasma concentrations achieved 30 min after dosing at 1 mg / kg. Thus, we evaluated the efficacy of PF-03550096 30 min after oral administration. To measure the pain threshold in response to colonic distension, we used behavioral signs of pain as an endpoint in the TNBS-induced visceral hypersensitivity model. This endpoint has been previously used and defined as a pain response in other studies because morphine showed potent efficacy on TNBS-induced visceral hypersensitivity (11) . Using this endpoint, we demonstrated that PF-03550096 significantly inhibited TNBS-induced visceral hypersensitivity; this effect was reversed by the CB 2 -selective antagonist SR144528. Agonist activity of PF-03550096 on rCB 2 receptors was not determined in vitro; however, reversal by SR144528 indicates that PF-03550096 behaved as a CB 2 agonist in rats. In addition, none of the rats showed abnormal behaviors at any dose. These results indicate that the pharmacological effects of PF-03550096 via CB 2 receptors are visceral analgesic ones. In a previous study using this model, Ohashi et al. observed infiltration of mast cells in the distal colon in the absence of inflammation by both the myeloperoxidase assay and histological examination (14) . It seemed possible that the accumulation of mast cells would be involved in visceral hypersensitivity to colonic distension. Given that activation of mast cells is inhibited via activation of CB 2 receptors in vitro (16, 17) , a possible mechanism of PF-03550096 action is inhibiting the release of pro-inflammatory mediators from mast cells in response to colonic distension. Patients suffering from IBS demonstrate lowered visceral sensory threshold to colorectal balloon distension, indicating visceral hypersensitivity (18, 19) . It has also been shown that there are increased numbers of mast cells in close proximity to nerve fibers in the colonic mucosa of some patients with IBS (20) . Barbara et al. demonstrated that mucosal mast cell mediators from IBS patients excite rat nociceptive visceral sensory nerves (21) . These data suggest that the infiltration and degranulation of intestinal mast cells are involved in altered excitability of primary afferent and enteric neurons, which are related to visceral hypersensitivity in IBS patients. Based on these findings, CB 2 -receptor agonists may represent therapeutic agents for treatment of visceral hypersensitivity via activation of CB 2 receptors expressed on mast cells. In conclusion, we have generated a novel CB 2 agonist, PF-03550096, that possesses efficacy in the TNBS-induced visceral hypersensitivity model in rats. Although the mechanism underlying the effects of PF-03550096 has not been fully elucidated, the higher selectivity for hCB 2 receptors suggests a possible use in treatment of functional gastrointestinal disorders characterized by visceral hypersensitivity, including irritable bowel syndromes.
